ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Lipid Abnormalities and Cardiovascular Events After Early Conversion to Everolimus in Kidney Transplant Recipients with Pretransplant Diabetes: 24-Month Analysis from Elevate Study.

M. van der Giet,1 J. de Fijter,1 F. Oppenheimer,1 G. Russ,1 P. Lopez,2 G. Bader,2 J. Cruzado,1 H. Holdaas.1

1ELEVATE Study Group, Berlin, Germany
2Novartis Pharma AG, Basel, Switzerland

Meeting: 2017 American Transplant Congress

Abstract number: D132

Keywords: Immunosuppression, Kidney transplantation, Lipids, Risk factors

Session Information

Date: Tuesday, May 2, 2017

Session Name: Poster Session D: Kidney: Cardiovascular and Metabolic

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Related Abstracts
  • Influence of Lipid Levels on Cardiovascular Events After Early Conversion from Calcineurin Inhibitor to Everolimus: 24 M Analysis of the ELEVATE Study.
  • Evolution of Lipid Profile and Major Adverse Cardiac Events in Kidney Transplant Recipients Converted from Calcineurin Inhibitor to Everolimus: 24-Month Subanalysis from Elevate Study.

PURPOSE: Pretransplant (preTx) diabetes is an independent risk factor for cardiovascular (CV) events, and posttransplant (post-Tx) hyperlipidemia further increases CV risk. To analyze the influence of preTx diabetes on CV outcomes, a 24-month (M) analysis of lipid profiles and CV outcomes in diabetic kidney transplant recipients (KTxRs) from the ELEVATE (NCT01114529) study, receiving everolimus (EVR) or standard calcineurin inhibitor (CNI) regimen, was performed.

METHODS: In this 24M, open-label, multicenter study, KTxRs were randomized at 10-14 weeks post-Tx to receive EVR (N=360; C0: 6-10ng/mL) or continue standard CNI regimen (N=357; C0: tacrolimus [TAC] 5-10ng/mL/cyclosporine A [CsA] 100-250ng/mL). Total-, high-density lipoprotein (HDL)-, and low-DL (LDL)- cholesterol (C) and triglyceride levels and incidence of CV events, including major adverse cardiac events (MACE), were assessed up to M24.

RESULTS: A total of 66 and 42 patients in EVR and CNI arms had preTx diabetes, respectively. Within CNI arm, 29 and 13 patients received TAC and CsA, respectively. High total-C (28.8%) and coronary heart disease (35.7%) were the most prevalent baseline CV risk factors in EVR and total CNI arms, respectively (Table). At M24, all lipid levels were significantly higher in EVR vs TAC arm (P<0.05), but not between EVR and CsA arms. While hypertriglyceridemia was absent, hypercholesterolemia events reported as adverse events were comparable between arms (P>0.999). Overall MACE incidence was numerically lower in EVR (7.6%) vs TAC (10.3%) and CsA (15.4%), and incidence of ischemic coronary artery disease was significantly lower in EVR vs CsA arm (0.0% vs 21.4%; P<0.01). Other CV events were comparable between arms.

CONCLUSION: Lower frequency of CV events despite higher lipid abnormalities in EVR vs CNI arms indicates that hyperlipidemia with EVR-based regimen may not increase CV risk in KTxRs even in presence of preTx diabetes. Nevertheless, follow-up beyond 24M is required to establish the long-term benefit of EVR in these patients.

CITATION INFORMATION: van der Giet M, de Fijter J, Oppenheimer F, Russ G, Lopez P, Bader G, Cruzado J, Holdaas H. Lipid Abnormalities and Cardiovascular Events After Early Conversion to Everolimus in Kidney Transplant Recipients with Pretransplant Diabetes: 24-Month Analysis from Elevate Study. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Giet Mvander, Fijter Jde, Oppenheimer F, Russ G, Lopez P, Bader G, Cruzado J, Holdaas H. Lipid Abnormalities and Cardiovascular Events After Early Conversion to Everolimus in Kidney Transplant Recipients with Pretransplant Diabetes: 24-Month Analysis from Elevate Study. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/lipid-abnormalities-and-cardiovascular-events-after-early-conversion-to-everolimus-in-kidney-transplant-recipients-with-pretransplant-diabetes-24-month-analysis-from-elevate-study/. Accessed April 23, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.